Viewing Study NCT02115906



Ignite Creation Date: 2024-05-06 @ 2:44 AM
Last Modification Date: 2024-10-26 @ 11:22 AM
Study NCT ID: NCT02115906
Status: UNKNOWN
Last Update Posted: 2016-09-27
First Post: 2014-04-11

Brief Title: Assessment of Changes in Metabolic Activity in Liver Skeletal Muscle in Patients Suffering From Acromegaly
Sponsor: Medical University of Vienna
Organization: Medical University of Vienna

Study Overview

Official Title: Assessment of Changes in Metabolic Activity in Liver Skeletal Muscle in Patients Suffering From Acromegaly - a 31P1H Magnetic Resonance Spectroscopy Pilot Study
Status: UNKNOWN
Status Verified Date: 2016-09
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Growth hormone GH plays a pivotal role in the regulation of body composition including ectopic lipid deposition in insulin sensitive organs like liver and skeletal muscle Recent evidence indicates that the GH-IGF1 axis affects body composition via regulating mitochondrial oxidation capacity

Thus excessive GH secretion by a pituitary adenoma Acromegaly might be accompanied by increased mitochondrial activity leading to inappropriately low intracellular lipid depots especially in metabolically active tissue like liver and skeletal muscle

This study aims to assess metabolic activity and intracellular lipid content in skeletal muscle and liver in patients suffering from acromegaly compared to controls by 31P1H Magnetic resonance spectroscopy before and in follow up examinations 3 6 and 12 months after initiation of GH lowering treatments including surgery somatostatinanalogs or pegvisomant as well as oral glucose tolerance tests at each examination to assess treatment responses and calculate validated parameters for insulin sensitivity and resistance
Detailed Description: Background Growth hormone GH plays a pivotal role in the regulation of body composition including ectopic lipid deposition in insulin sensitive organs like liver and skeletal muscle Direct inhibition of growth hormone action by a receptor antagonist has been shown to induce hepatic steatosis and growth hormone replacement decreases liver fat content in obese humans Of note recent evidence indicates that the GH-IGF1 axis affects body composition via regulating mitochondrial oxidation capacity

Hypothesis Direct andor indirect effects of GH on mitochondrial function might mediate the changes in body composition and lipid deposition Thus excessive GH secretion by a pituitary adenoma Acromegaly might be accompanied by increased mitochondrial activity leading to inappropriately low intracellular lipid depots especially in metabolically active tissue like liver and skeletal muscle

Aim Assessment of metabolic activity and intracellular lipid content in skeletal muscle and liver in patients suffering from acromegaly compared to controls

Methods Non-interventional study

31P1H Magnetic resonance spectroscopy before and in follow up examinations 3 6 and 12 months after initiation of GH lowering treatments including surgery somatostatinanalogs or pegvisomant
oral glucose tolerance tests at each examination to assess treatment responses and calculate validated parameters for insulin sensitivity and resistance

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None